The HeartWare ventricular assist device (HVAD) was discontinued in July 2021. The study aims to describe the impact the discontinuation the HVAD had on pediatric ventricular assist device (VAD) utilization and outcomes.
Patients with Fontan failure are high-risk candidates for heart transplantation and other advanced therapies. Understanding the outcomes following initial heart failure consultation can help define appropriate timing of referral for advanced heart failure care.
ACTION set forth to report current outcomes in patients supported with the HeartMate 3 ventricular assist device in a multicenter learning network.
IMPROVING STROKE OUTCOMES IN CHILDREN SUPPORTED WITH A VENTRICULAR ASSIST DEVICE IN A QUALITY IMPROVEMENT NETWORK ACTION has been working to reduce the frequency of stroke associated with pediatric VAD …
